Success in Biotech is about more than breakthrough science. It requires companies to navigate funding rounds, development milestones, investor scrutiny and commercial decision-making, all while building an intellectual property position that supports long-term value creation.
In this panel discussion, experienced biotech founders, executives and advisers will explore the realities of the biotech growth journey – from early-stage investment through to clinical and regulatory milestones, strategic partnerships, acquisitions, and IPOs. The conversation will highlight the importance of alignment between IP strategy and the evolving priorities of the business, helping companies secure funding, manage risk and maximise value at every stage of their development.
Our panellists:
Priya Mande, CEO of RNAvate
Kevin Tipping, Transactions Director at AstraZeneca
More panellists will be revealed soon.
The discussion will explore:
Securing early-stage and growth funding, from seed investment to Series A and beyond
Navigating investor expectations and due diligence processes
Building an effective IP strategy to support fundraising and commercial objectives
Working successfully with patent advisors to protect innovation
Commercialisation pathways, including licensing, partnerships, acquisitions and long-term growth strategies
Key lessons learned and practical advice for founders, entrepreneurs and innovators
The session will conclude with an interactive Q&A, providing attendees with the opportunity to engage directly with the panel and explore the challenges and opportunities facing biotech companies today. The event will be followed by a networking session with drinks, with an unbeatable view across the City of London.